Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CPC-201 in Alzheimer's Dementia Extension
NCT02434666Phase 2Completed
- Sponsor
- Allergan
- Start
- Jan 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donepezil + solifenacin in Alzheimer's disease (AD), sponsored by Allergan. Started Jan 2015; status: completed.
02
Drugs
donepezil + solifenacin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02434666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434666.